The embolotherapy market size is expected to increase from USD 3.99 billion in 2025 to USD 4.28 billion in 2026 and reach USD 6.10 billion by 2031, growing at a CAGR of 7.34% over 2026-2031. This report is Segmented by Product Type (Embolic Agents, Embolization Coils, and More), Procedure (Transarterial Chemoembolization, and More), Disease Indication (Oncology, Benign Tumors, Vascular Abnormalities, and More), End User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Other drivers and restraints analyzed in the detailed report include:
The premium segment of this category is evolving rapidly. Resorbable and conformable liquid embolics are shifting the focus from vessel occlusion to treatment planning and follow-up flexibility. Embolization coils, especially valued in neurovascular and complex peripheral applications, emphasize repositionability and control. Vascular plugs and plug systems, projected to grow at a 7.99% CAGR through 2031, are increasingly utilized in prostate artery embolization, fibroid procedures, and trauma cases requiring controlled occlusion.
TACE accounted for 34.40% of the embolotherapy market in 2025, making it the leading procedure by revenue. Its dominance is attributed to its established role in hepatocellular carcinoma, integration into treatment pathways, and widespread adoption in academic and community hospitals. TACE's procedural familiarity supports its repeated use in liver-directed oncology and extends its application to metastases, neuroendocrine tumors, and other hypervascular lesions. This versatility ensures TACE remains central to routine embolic practices, even as newer procedures gain attention.
TARE, projected to grow at an 8.25% CAGR through 2031, is gaining traction due to its clinical preference in specific patient demographics. A meta-analysis spanning 2024 to 2025 highlighted TARE's superior response, disease control, and one-year survival rates compared to TACE, alongside fewer common complications. A 2025 study showcased an 83% objective response rate and a median overall survival of 47.2 months for HCC patients with portal vein invasion undergoing Y-90 glass microsphere therapy.
In 2025, Europe held a significant share of the embolotherapy market, supported by advanced hospital systems in Germany, France, and the U.K. These countries benefit from well-developed interventional radiology departments and centralized oncology networks, enabling procedures like TACE, TARE, fibroid embolization, and neurovascular treatments. A German study documented 718 middle meningeal artery embolization procedures across 30 neurovascular centers, reflecting specialist density and growing clinical acceptance. Italy and Spain contribute to liver-directed oncology volumes, partly due to historical hepatitis-related disease burdens. Europe plays a key role in protocol development, product validation, and specialist training, influencing the global embolotherapy market.
Asia-Pacific is projected to achieve the fastest regional CAGR of 8.45% through 2031, emerging as the strongest growth driver for the embolotherapy market. The region faces a rising burden of hepatocellular carcinoma, particularly in areas with high HBV prevalence. China and India are expanding interventional radiology capacity, increasing access to embolization procedures beyond major urban centers. Japan is advancing clinical and regulatory pathways for middle meningeal artery embolization, signaling a growing neurovascular focus.
Global Embolotherapy Market Trends and Insights
Rising Burden of Cancer and Hypervascular Tumors
The embolotherapy market is closely tied to the global cancer burden, as embolization is critical for treating diseases with high vascular activity. Global cancer cases are projected to reach 20 million in 2025, with a significant rise expected by 2050, ensuring a growing patient base for embolic procedures. This trend is particularly evident in liver cancer, renal tumors, and bone lesions, where managing tumor blood supply is vital for both curative and palliative treatments. Demand is also shifting geographically, with Asia-Pacific and parts of Africa experiencing a rise in HBV- and HCV-related liver cancer cases, driving the need for TACE and similar procedures. Manufacturers are adapting product designs, pricing, and training to cater to a broader range of hospitals.Expanding Use of Minimally Invasive Image-Guided Procedures
The embolotherapy market is benefiting from a shift toward catheter-based treatments in oncology, trauma, and vascular care. Enhanced imaging techniques, such as cone-beam CT and advanced fluoroscopic guidance, are improving distal vessel access and reducing procedural uncertainties. This shift enables more precise treatments and lowers technical barriers, allowing community hospitals and mid-sized centers to handle complex embolic cases. Newer coil systems are being designed to enhance workflow efficiency and reduce device burdens during large-vessel embolizations. As a result, the market is expanding through both rising disease incidences and broader procedural adoption across care settings.Reimbursement Variability Across Indications and Care Settings
The embolotherapy market faces reimbursement challenges as the expansion of medical indications often outpaces payer frameworks in many countries. While oncology applications have clearer billing pathways, newer uses in neurology and urology lack consistency. In the U.S., evolving payer policies for novel materials and applications delay hospital formulary adoption and broader market rollouts. In Europe, variations in health technology assessments and payer interpretations across countries result in uneven access, even with regulatory approvals. Premium-priced next-generation embolics are initially adopted in high-volume centers with coding expertise, specialized staff, and robust internal review processes, slowing the market's ability to achieve widespread commercial success.Other drivers and restraints analyzed in the detailed report include:
- Broader Adoption of Liquid and Resorbable Embolic Agents
- Evidence Generation for New Indications: Middle Meningeal Artery Embolization
- High Per-Case Device Cost and Inventory Complexity
Segment Analysis
In 2025, embolic agents held a dominant 58.77% share of the embolotherapy market, surpassing all other product categories. This leadership stems from the widespread use of microsphere-based TACE, particle embolization, and the expanding liquid embolic class, all integral to interventional oncology. Unlike other product types confined to specific procedures, this group thrives across diverse treatment settings. Drug-eluting microspheres enhance local chemotherapy delivery while minimizing systemic exposure, while newer liquid systems offer flexibility for repeat or staged cancer treatments. Even with increasing emphasis on pricing and clinical differentiation, embolic agents remain the cornerstone of the embolotherapy market's revenue.The premium segment of this category is evolving rapidly. Resorbable and conformable liquid embolics are shifting the focus from vessel occlusion to treatment planning and follow-up flexibility. Embolization coils, especially valued in neurovascular and complex peripheral applications, emphasize repositionability and control. Vascular plugs and plug systems, projected to grow at a 7.99% CAGR through 2031, are increasingly utilized in prostate artery embolization, fibroid procedures, and trauma cases requiring controlled occlusion.
TACE accounted for 34.40% of the embolotherapy market in 2025, making it the leading procedure by revenue. Its dominance is attributed to its established role in hepatocellular carcinoma, integration into treatment pathways, and widespread adoption in academic and community hospitals. TACE's procedural familiarity supports its repeated use in liver-directed oncology and extends its application to metastases, neuroendocrine tumors, and other hypervascular lesions. This versatility ensures TACE remains central to routine embolic practices, even as newer procedures gain attention.
TARE, projected to grow at an 8.25% CAGR through 2031, is gaining traction due to its clinical preference in specific patient demographics. A meta-analysis spanning 2024 to 2025 highlighted TARE's superior response, disease control, and one-year survival rates compared to TACE, alongside fewer common complications. A 2025 study showcased an 83% objective response rate and a median overall survival of 47.2 months for HCC patients with portal vein invasion undergoing Y-90 glass microsphere therapy.
Complete Report Scope:
- By Product Type
- Embolic Agents
- Liquid Embolic Agents
- Microspheres
- Particles
- Sclerosants and Adhesives
- Embolization Coils
- Detachable Coils
- Pushable Coils
- Vascular Plugs and Plug Systems
- Flow Diverters
- Support Devices
- Microcatheters
- Guidewires
- Embolic Agents
- By Procedure
- Transarterial Chemoembolization
- Transarterial Radioembolization
- Transcatheter Arterial Embolization
- Stent-Assisted Coiling
- Particle Embolization
- Sac Packing
- Sandwich Technique
- By Disease Indication
- Oncology
- Benign Tumors
- Vascular Abnormalities
- Hemorrhage and Trauma
- Neurology
- Urology and Nephrology
- Peripheral Vascular Disease
- By End User
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Academic and Research Institutes
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
In 2025, North America accounted for 38.79% of the embolotherapy market, maintaining its position as the largest regional contributor. This dominance stems from a strong interventional radiology infrastructure, a wide procedural base in oncology and women’s health, and regulatory support for innovative product approvals. The U.S. serves as the primary launch platform for new embolic technologies, providing early market access. North America is also central to the growth of middle meningeal artery embolization, with procedure volumes expected to approach acute ischemic stroke treatment levels by 2029.In 2025, Europe held a significant share of the embolotherapy market, supported by advanced hospital systems in Germany, France, and the U.K. These countries benefit from well-developed interventional radiology departments and centralized oncology networks, enabling procedures like TACE, TARE, fibroid embolization, and neurovascular treatments. A German study documented 718 middle meningeal artery embolization procedures across 30 neurovascular centers, reflecting specialist density and growing clinical acceptance. Italy and Spain contribute to liver-directed oncology volumes, partly due to historical hepatitis-related disease burdens. Europe plays a key role in protocol development, product validation, and specialist training, influencing the global embolotherapy market.
Asia-Pacific is projected to achieve the fastest regional CAGR of 8.45% through 2031, emerging as the strongest growth driver for the embolotherapy market. The region faces a rising burden of hepatocellular carcinoma, particularly in areas with high HBV prevalence. China and India are expanding interventional radiology capacity, increasing access to embolization procedures beyond major urban centers. Japan is advancing clinical and regulatory pathways for middle meningeal artery embolization, signaling a growing neurovascular focus.
List of Companies Covered in this Report:
- Abbott Laboratories
- Acandis
- Asahi Intecc Co., Ltd.
- B. Braun
- Balt Extrusion
- Boston Scientific
- Cook Group
- Guerbet
- Inari Medical
- Johnson & Johnson
- Kaneka
- Medtronic
- Merit Medical Systems
- MicroVention
- Penumbra
- Shape Memory Medical
- Sirtex Medical Pty Ltd
- Stryker
- Terumo
- Wallaby Medical
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 INTRODUCTION
4 MARKET LANDSCAPE
5 MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)
6 COMPETITIVE LANDSCAPE
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Acandis GmbH
- Asahi Intecc Co., Ltd.
- B. Braun SE
- Balt Extrusion
- Boston Scientific Corporation
- Cook Medical LLC
- Guerbet
- Inari Medical, Inc.
- Johnson and Johnson
- Kaneka Corporation
- Medtronic plc
- Merit Medical Systems, Inc.
- MicroVention, Inc.
- Penumbra, Inc.
- Shape Memory Medical Inc.
- Sirtex Medical Pty Ltd
- Stryker Corporation
- Terumo Corporation
- Wallaby Medical
